S-1/A: Femasys Inc. Launches Public Offering Amid Nasdaq Delisting Concerns

Femasys Inc. is offering up to 11.4 million shares and warrants to raise capital, while simultaneously addressing Nasdaq delisting notices and a 'going concern' warning.

Summary

• Femasys Inc. is conducting a public offering of up to 11,428,571 shares of common stock and accompanying common warrants.
• Pre-funded warrants are also offered as an alternative for large purchasers to avoid exceeding beneficial ownership limits, exercisable for a nominal $0.0001 per share.
• Each share or pre-funded warrant is sold together with one common warrant, which will have an exercise price of 100% of the public offering price and will expire five years from issuance.
• The assumed public offering price for each share of common stock and accompanying common warrant is $0.70, based on the Nasdaq closing price on August 18, 2025.
• The company expects to receive estimated net proceeds of $7.2 million from this offering, after deducting underwriting discounts and commissions and estimated offering expenses.
• Proceeds are intended for product development, general corporate purposes, capital expenditures, working capital, and general and administrative expenses, with potential for future acquisitions or investments.
• As of June 30, 2025, actual cash and cash equivalents were $3,218,067, projected to increase to $10,408,067 post-offering.
• The company has convertible notes payable, net, of $6,080,813 as of June 30, 2025, which are due in November 2025.
• Femasys received Nasdaq delisting notices for failing to meet the minimum $35.0 million Market Value of Listed Securities (MVLS) requirement (May 19, 2025, with a 180-day compliance period until November 17, 2025) and the minimum $1.00 bid price requirement (July 16, 2025, with a 180-day compliance period until January 12, 2026).
• The company is a biomedical innovator in women's health with a portfolio including FemaSeed (infertility treatment), FemVue (fallopian tube assessment), FemCerv (cervical cancer diagnosis), and FemBloc (permanent birth control).
• FemBloc received Conformit Europenne (CE) mark certification in the EU (March 2025 for the delivery system, June 2025 for the blended polymer component) and UK approval (August 2025), with a pivotal U.S. clinical trial currently enrolling participants.
• The company launched its FemSperm Setup Kit in August 2025, designed to enable gynecologists for FemaSeed Intratubal Insemination.

Sentiment

Score: 3

Explanation: The company is undertaking a significant capital raise to address immediate financial challenges, including Nasdaq delisting threats and a 'going concern' warning. While product development and recent international approvals are positive, the underlying financial health and the need for this dilutive offering indicate a distressed situation. The future success hinges on successful commercialization and regaining Nasdaq compliance.

Positives

• Recent global regulatory approvals for FemBloc, including CE mark certification in the European Union (March 2025 and June 2025) and approval in the UK (August 2025).
• Pivotal U.S. clinical trial for FemBloc permanent birth control is actively enrolling participants, indicating progress towards potential U.S. market entry.
• FemaSeed intratubal insemination is U.S. FDA-cleared and approved in multiple international markets (Europe, UK, Canada, Israel, Australia, New Zealand), supported by positive peer-reviewed clinical trial data.
• Introduction of the FemSperm Setup Kit in August 2025 expands the FemaSeed product family, aiming to enhance gynecologist capabilities for the procedure.
• The company possesses a broad, internally created intellectual property portfolio with over 200 issued patents globally, providing a competitive advantage.
• The offering is expected to significantly increase cash and cash equivalents from $3,218,067 to $10,408,067, providing crucial capital for operations and product development.

Negatives

• Received two Nasdaq delisting notices: one for failing the minimum $35.0 million Market Value of Listed Securities (MVLS) requirement (May 19, 2025) and another for failing the minimum $1.00 bid price requirement (July 16, 2025).
• The audit report from KPMG LLP includes an explanatory paragraph raising 'substantial doubt about the entity's ability to continue as a going concern' due to recurring losses, negative cash flows, and a net capital deficiency.
• Convertible notes payable of $6,080,813 are due in November 2025, representing a significant near-term financial obligation.
• New investors in this offering will experience immediate and substantial dilution of approximately $0.50 per share.
• There is no established public trading market for the pre-funded warrants or common warrants, which will limit their liquidity.
• The company's common stock trading price has been, and is expected to remain, highly volatile.

Risks

• Ability to obtain additional financing to fund commercialization of products and operations.
• Ability to obtain additional financing to fund the U.S. clinical development of FemBloc permanent birth control.
• Ability to pay convertible notes due November 2025 if not converted into common stock.
• Ability to obtain U.S. Food and Drug Administration (FDA) approval for FemBloc.
• Ability to successfully grow sales of FemaSeed intratubal insemination in the U.S. and FemBloc permanent birth control in the European Union.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for FemBloc or any future product candidates.
• Ability to accurately forecast customer demand for products and manage inventory.
• Ability to build, manage, and maintain a direct sales and marketing organization.
• Ability to continue operating as a going concern.
• Risks related to clinical trials, including demonstrating safety and effectiveness of FemBloc and timely subject enrollment.
• Ability to manufacture products in compliance with applicable laws and regulations and oversee third-party suppliers.
• Ability to hire and retain senior management and other highly qualified personnel.
• FDA or other U.S. or foreign regulatory actions affecting the company or the healthcare industry generally.
• Timing or likelihood of regulatory filings and approvals or clearances.
• Ability to establish and maintain intellectual property protection for products and product candidates and avoid claims of infringement.
• Volatility of the trading price of common stock.
• Risk of delisting from Nasdaq due to non-compliance with Market Value of Listed Securities (MVLS) and minimum bid price requirements.
• Broad discretion of management in how the net proceeds from this offering are used.
• Immediate and substantial dilution for new investors.
• Future dilution as a result of potential future equity offerings.
• No public market for the pre-funded warrants or the common warrants, limiting their liquidity.
• Potential for substantial sales of common stock in the market following this offering, which may depress the market price.

Future Outlook

The company intends to use the net proceeds from this offering for the development of its products and product candidates, general corporate purposes, capital expenditures, working capital, and general and administrative expenses, with a potential for future acquisitions or investments. It aims to continue growing sales of FemaSeed in the U.S. and FemBloc in the EU, and is advancing FemBloc's U.S. clinical development towards FDA approval. The company is actively monitoring its Nasdaq listing compliance and may consider a reverse stock split if necessary to meet the minimum bid price requirement.

Management Comments

• "We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split."
• "We intend to actively monitor the MVLS of our common stock between now and November 17, 2025, and will consider our available options to regain compliance with the Minimum MVLS Requirement."
• "We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future."

Industry Context

Femasys operates in the women's health biomedical sector, focusing on addressing significant unmet needs with disruptive, accessible, in-office therapeutic and diagnostic products. The company highlights its broad patent-protected portfolio and global regulatory approvals, positioning itself as an innovator in multi-billion dollar global market segments that have seen little advancement. Its non-surgical FemBloc permanent birth control system is presented as a revolutionary alternative to traditional surgical sterilization, offering potential benefits like safety, accessibility, and lower cost, aligning with a broader industry trend towards less invasive medical procedures.

Comparison to Industry Standards

• The company's FemBloc non-surgical permanent birth control is presented as a 'revolutionary first-in-class' solution, contrasting it with 'centuries-old surgical sterilization' which carries reported risks such as infection, bleeding, organ injury, anesthesia-related events, and even death. This implies a significant improvement over existing surgical standards.
• The filing does not provide specific comparable companies, projects, or detailed numerical results for direct industry-specific benchmarks, but generally states that its products address 'multi-billion dollar global market segments in which there has been little advancement for many years,' suggesting it aims to set new standards rather than just meet existing ones.

Corporate Governance

Legal Proceedings

• No action, suit, inquiry, notice of violation, proceeding, or investigation is pending or, to the company's knowledge, threatened against or affecting the company that would adversely affect the legality, validity, or enforceability of the offering or result in a Material Adverse Effect.
• Neither the company nor any director or officer has been the subject of any legal action involving a claim of violation of federal or state securities laws or a claim of breach of fiduciary duty.
• No investigation by the SEC involving the company or its current or former directors or officers is pending or contemplated.
• No stop order or other order suspending the effectiveness of any registration statement filed by the company has been issued by the SEC.
• No pending or threatened administrative, regulatory, or judicial actions, suits, demands, or proceedings relating to any Environmental Law against the company that would result in a Material Adverse Effect.

Related Party Transactions

• The May 2025 Private Placement included the purchase of 98,040 shares by certain directors and officers at a price of $1.02 per share.
• Convertible notes payable, net, as of June 30, 2025, include amounts related to related parties.
• The company states that, except as disclosed in the General Disclosure Package, no officers, directors, or employees are party to any material transaction with the company (other than employment-related compensation) in excess of $120,000.

Stakeholder Impact

• Shareholders: Existing shareholders will experience significant immediate dilution due to the offering. The capital raise aims to address financial distress and Nasdaq listing issues, which could stabilize or improve share price long-term if successful, but carries delisting risk if unsuccessful.
• Employees: The capital raise could help fund ongoing operations and product development, potentially securing employment and supporting future growth initiatives.
• Customers: Continued product development and commercialization efforts, supported by the offering's proceeds, could lead to new or improved women's health solutions being brought to market.
• Creditors: The capital raise provides funds to address financial obligations, including convertible notes due in November 2025, which could improve the company's ability to meet its debt obligations.

Next Steps

• Complete the public offering of common stock and warrants to secure estimated net proceeds of $7.2 million.
• Continue U.S. clinical development and enrollment for FemBloc permanent birth control towards FDA approval.
• Grow sales of FemaSeed in the U.S. and FemBloc in the European Union.
• Monitor and work to regain compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement by November 17, 2025.
• Monitor and work to regain compliance with Nasdaq's Minimum Bid Price Requirement by January 12, 2026, potentially considering a reverse stock split.
• Address the maturity of convertible notes totaling $6,080,813 in November 2025.
• Utilize net proceeds for product development, general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
• Potentially acquire or invest in complementary businesses, products, and technologies.

Key Dates

Recommendation

The company is at a critical juncture, facing Nasdaq delisting and a 'going concern' warning, which are significant negative indicators. However, the current offering provides a much-needed capital injection to address these immediate financial pressures and fund ongoing product development and commercialization efforts. The company's product pipeline, particularly FemBloc with recent international approvals and a U.S. pivotal trial, shows strong potential in a large market. The recommendation is 'hold' because while the risks are substantial and the stock is highly volatile, the company is actively pursuing strategies to overcome its challenges, and its innovative products offer long-term upside if successfully commercialized and regulatory hurdles are cleared. Investors should monitor Nasdaq compliance and commercial progress closely.

Keywords

Femasys Inc., FEMY, Women's Health, Biomedical, Medical Devices, Infertility Treatment, Birth Control, FemBloc, FemaSeed, FemVue, SEC Filing, S-1/A, Public Offering, Nasdaq Delisting, Going Concern, Warrants, Pre-funded Warrants, Capital Raise, Clinical Trials, FDA Approval, CE Mark, Intellectual Property